CN1526721A - Extraction process of conjugated female hormone - Google Patents
Extraction process of conjugated female hormone Download PDFInfo
- Publication number
- CN1526721A CN1526721A CNA031138586A CN03113858A CN1526721A CN 1526721 A CN1526721 A CN 1526721A CN A031138586 A CNA031138586 A CN A031138586A CN 03113858 A CN03113858 A CN 03113858A CN 1526721 A CN1526721 A CN 1526721A
- Authority
- CN
- China
- Prior art keywords
- water
- resin
- elutriant
- organic solvent
- collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005556 hormone Substances 0.000 title claims abstract description 10
- 229940088597 hormone Drugs 0.000 title claims abstract description 10
- 238000000605 extraction Methods 0.000 title description 10
- 239000011347 resin Substances 0.000 claims abstract description 45
- 229920005989 resin Polymers 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 37
- 210000002700 urine Anatomy 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000003960 organic solvent Substances 0.000 claims description 16
- 239000003463 adsorbent Substances 0.000 claims description 13
- 125000003375 sulfoxide group Chemical group 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 229940011871 estrogen Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 7
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 238000003795 desorption Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000001076 estrogenic effect Effects 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000005192 partition Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000015606 cardiovascular system disease Diseases 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the extracting process of conjugated female hormone from urine of pregnant mare with polar adsorbing resin containing sulfoxide radical and Eluex process of eluting the extracted resin. The combination of the extracting process with polar adsorbing resin containing sulfoxide radical and the Eluex process of eluting the extracted resin is favorable to raising selective adsorption and desorption of female hormone and to raising the recovering rate of female hormone. The said method of the present invention is simple, low in cost and favorable to industrial production.
Description
The present invention relates to a kind of from pregnant horse urine liquid (Pregnant Mare ' s Urine, PMU) the middle method of extracting combined female hormone (Conjugated Estrogen).
The combined female hormone that extracts from pregnant horse urine liquid is mainly used in Hormone Replacement Therapy (Estrogen Replacement Therapy, ERT), be used for the treatment of climacteric syndrome, cardiovascular system diseases and the osteoporosis that can effectively prevent and treat.
Oestrogenic hormon is the class importance glandular hormone in the animal body, belongs to the steroid hormone of steroid.The breeding physiology of jenny is subjected to the dominant force of nervus centralis and pituitary gland portion, is also directly accepting main hormonal effects by ovarian secretion.The dam Gestation period and just before giving birth before and after, the significant variation takes place in internal secretion, estrogenic physiological action is suppressed, but its generation still carrying out, so the estrogen content in the Gestation period dam movement significantly increase, particularly remarkable in this phenomenon of mare.
In the sixties in 20th century, adopt the estrogenic Hormone Replacement Therapy of pregnant horse urine to begin to rise in the U.S. and Canada, the consequent is Hormone Replacement Therapy and climacteric women carcinoma of endometrium, the pass that mammary cancer takes place ties up to medical circle and also has dispute, and view differs.But along with the aging problem becomes increasingly conspicuous in many countries, the threat that the fracture that the cardiovascular system diseases of the low initiation of body inner estrogen level and osteoporosis cause causes elderly woman life again day by day seriously, the nineties in 20th century coronary heart disease become postmenopausal women's first cause of the death in developed country.Still do not have other treatment except that Hormone Replacement Therapy, oestrogenic hormon lacks the effective ways of the climacteric syndrome of initiation.
The main method of extraction that adopts is separated extraction combined oestrogenic hormon from pregnant horse urine in the research in early days, United States Patent (USP) 2519516 is arranged, 2696265,2834712, English Patent 2017906, Australian Patent 6426999, the method of its extraction adopts organic low-carbon alcohol, ester, halohydrocarbon etc., the method of abstraction purification removal of impurities through three to eight steps is carried out, and main problem is that the extracting and emulsifying problem is serious, causes problems such as the low and oestrogenic hormon rate of recovery of separation efficiency is low.In the research in later stage, adopt absorption to resolve technology, comprise United States Patent (USP) 2551205,5723454, Russ P 2179028, Slovakia's patent 24499 mainly adopts gac, silica gel, ion exchange resin etc.; And Chinese patent 1308083,1228027,1234740, adopt polar resin, silica gel and the semi-polarity resin of cyano-containing respectively.There are the regeneration difficulty in early stage sorbent material such as activated carbon, silica gel etc., the problem that adsorption efficiency is low, and the later stage sorbent material comprises ion exchange resin, and the Polar Adsorbent Resin of cyano-containing is regenerated easily but saturated capacity is low, and adsorption selectivity is poor.
The present invention mainly describes the estrogenic method of Polar Adsorbent Resin extraction pregnant horse urine that a kind of utilization contains sulfoxide group, and a kind of eluex process that is applied to the resin parsing of initiative proposition.
Make the polymeric adsorbent of load with the Polar Adsorbent Resin that contains sulfoxide group, mainly be to have utilized the sulfoxide group Polar Adsorbent Resin of macroporous netlike to carry out isolating to the selective adsorption effect of effective constituent, elder generation is with pregnant horse urine and resin is dynamic or Static Contact, the combined mixed estrin just is attracted on the post, use the organic solvent wash-out again, resolve afterwards, through concentrating, be drying to obtain the pregnant Sterones mixture of combined.
The brand-new type of elution of a kind of resin absorption material of Kai Chuanxing proposition is drenched the collection process in the present invention.This is a kind of separating substances process of physics, and principle is in the drip washing equilibrium process, has the secondary distribution balance of extraction process simultaneously.Conventional resin elution liquid is generally used low-carbon alcohol, ketone, and ether, ester isopolarity material washs.The drip washing flow process that the present invention proposes just is to exist twice partition equilibrium, estrogenic once balance in leacheate and the resin, and the secondary balancing of wash-out host and extraction agent in the washings, this chemical separation process has been successfully applied to nuclear industry at present, obtains the unusual effect that improves partition ratio.
In the process of the wash-out effective ingredient of resin, there is the partition equilibrium process that is incorporated on the resin and is dissolved in elutriant in effective ingredient.In static resolving, use a certain amount of elutriant to soak saturated resin, stir and make resin and elutriant thorough mixing, make after a period of stabilisation, change elutriant.In the static mixing elution process, along with the increase of time, do not have more effective ingredient and eluted, must change fresh eluent, can prove thus to have effective constituent in the partition equilibrium on the resin and between the elutriant.Owing to have this partition equilibrium, so elutriant can elute effective ingredient in batches.We call the drip washing balance to this partition equilibrium.
Drenching the collection process is exactly to increase one or several organic solvents in elutriant, makes to remove in the elution process to have the drip washing balance external, increases the secondary distribution balance, i.e. extraction equilibrium.Organic solvent adopts the insoluble or sl. sol. organic solvent of water, and this organic solvent can be polar solvent or non-polar solvent.General resin elution liquid is the aqueous solution that contains water-miscible organic solvent, and minority can adopt pure organic solvent.Organic component in these elutriants can make to the extraction agent of realizing that eluex process adds, is dissolved in the stable homogeneous phase of formation in the elutriant; Perhaps the part extraction agent can not be dissolved in eluent fully, and the suitable tensio-active agent of suitable interpolation can form stable homogeneous phase.
The key of drenching the collection process is that water does not dissolve or sl. sol. organic solvent at the organic solvent that is used to extract purpose.
The treatment process of drenching the collection elutriant has two kinds, and a kind of is to handle according to normal elutriant, and another kind is to increase tensio-active agent to make the elutriant layering in elutriant, forms biphasic system, will contain a phase of high-purity effective ingredient, further processes.
The major advantage of drenching the collection process is to have twice or twice above partition equilibrium, can effective constituent be got off from resin drip washing with less elutriant, improve the concentration of effective ingredient in the elutriant, improve the separation factor between the isolate simultaneously, obtain the higher effective ingredient of purity.
Drench the polar resin of finding to contain sulfoxide group in the collection process in research, help the estrogenic absorption of combined and drench collection resolving.
The step of extracting combined female hormone from pregnant horse urine liquid that the present invention describes comprises following content:
1, with pregnant horse urine by containing the polar resin of sulfoxide group, online detection.
2, wash resin with water.
3, the elutriant with preparation drenches collection resolving.
4, the elutriant that will drench collection carries out aftertreatment, and concentrate drying obtains combined estrogen mixture solid.
The pregnant horse urine of mentioning in step 1 is not for containing or contain the pregnant horse urine of a small amount of suspended substance.Contain suspended substance and be unfavorable for resin absorption, should advanced processing to remove most suspended substances, method can be conventional process such as ultrafiltration, centrifuging, press filtration.
The resin of mentioning in step 1 is the polar resin that contains sulfoxide group.
That mentions in step 2 washes resin with water, can adopt the neutral water washing, or the alkaline water washing, or earlier with the neutral water washing, uses the alkaline water washing resin again.
Elutriant composition in step 3 is: water; A kind of can with the low-carbon alcohol of water mutual solubility, ketone, ester isopolarity organic solvent, including but not limited to ethanol, methyl alcohol, acetone; And the insoluble or sl. sol. low-carbon alcohol of one or several water, ketone, organic solvents such as haloalkane, including but not limited to ethyl acetate, n-hexyl alcohol, hexalin, propyl carbinol, chloroform.
Elutriant in step 3 can be pH value neutrality.
Elutriant in step 3 can be regulated PH and be alkalescence, increases elute effect, and the PH scope is 8～13, need in the last handling process in step 5 to require to regulate earlier pH value simultaneously for neutral;
In step 3, drenching the collection temperature is normal temperature wash-out or heating wash-out, heats favourable to resolving.Temperature range is below 65 ℃.
Last handling process in step 4 can be for directly concentrated, dry; Also can add tensio-active agent and make water-insoluble organic solvent and aqueous phase separation.The reconcentration drying.If elutriant is an alkalescence in the step 3, it is neutral needing to regulate earlier pH value.
The renovation process of polymeric adsorbent can adopt conventional polymeric adsorbent treatment process, with 75% left and right sides ethanol elution regeneration, can adopt 1NHCL and 1NNaOH to handle in case of necessity.
In the following embodiments, merge second and third column volume elutriant, spraying drying obtains containing the light yellow solid powder of combined mixed estrin, and wherein the combined estrogen content can reach more than 15%.Be better than adopting the effect of ordinary resin wash-out, and the oestrogenic hormon wash-out is more concentrated, can form hangover.
The oestrogenic hormon of mentioning in the following example of the present invention all refers to combined oestrogenic hormon, and the estrogenic analytical procedure of combined is that HPLC detects, and column volume refers to be equivalent to the resin column volume in the following example.
Embodiment one:
Contain the estrogenic horse urine of 40mg/l with 2.5 liters and pass through 30 milliliters of Polar Adsorbent Resin (commercially available, Chemical Plant of Nankai Univ.) that contain sulfoxide group, dynamic adsorption.Wash resin with water to colourless, shared water 90ml.Be 10 water washing resin then with pH value, to colourless, shared water 90ml.Eluent is a water: ethanol: the ethyl acetate ratio is 45: 35: 20.The normal temperature wash-out, elutriant is collected four column volumes.
Embodiment two:
Contain the estrogenic horse urine of 35mg/l with 3 liters and pass through 30 milliliters of Polar Adsorbent Resin that contain sulfoxide group, dynamic adsorption.Washing resin with water to colourless, is 11 water washing resin with pH value, to colourless then.Eluent is a water: ethanol: the hexalin ratio is 50: 30: 20, pH value 11.55 ℃ of wash-outs are collected four column volumes.
| Embodiment number | |||
| Horse urine initial concentration | ??40mg/l | ????35mg/l | ????35mg/l |
| Elutriant | Water/ethanol/ethyl acetate 45: 35: 20 | Water/ethanol/50: 30: 20 PH11 of hexalin | Water/ethanol/50: 25: 25 PH10 of propyl carbinol |
| Eluting temperature | Normal temperature | ????55℃ | Normal temperature |
| The first column volume concentration | ??0 | ????0 | ????0 |
| The second column volume concentration | ??1246mg/l | ????1356mg/l | ????954mg/l |
| The 3rd column volume concentration | ??939mg/l | ????856mg/l | ????1183mg/l |
| The 4th column volume concentration | ??32mg/l | ????29mg/l | ????83mg/l |
Embodiment three:
Contain the estrogenic horse urine of 35mg/l with 3 liters and pass through 30 milliliters of Polar Adsorbent Resin that contain sulfoxide group, dynamic adsorption.Washing resin with water to colourless, is 10 water washing resin with pH value, to colourless then.Eluent is a water: ethanol: the propyl carbinol ratio is 50: 25: 25, and elutriant is transferred pH value 10.The normal temperature wash-out is collected four column volumes.
Claims (5)
1, from pregnant horse urine liquid, extract the method for combined female hormone, be characterized in:
A) with pregnant horse urine by containing the Polar Adsorbent Resin of sulfoxide group.
B) wash resin with water.
C) elutriant with preparation drenches collection resolving.
D) elutriant that will drench collection carries out aftertreatment, and concentrate drying obtains combined estrogen mixture solid.
2, a kind of polymeric adsorbent effective ingredient is drenched the method for collection wash-out.Be characterized in eluent by water, a kind of can with the organic solvent of water mutual solubility, and one or several organic solvents water insoluble or that be slightly soluble in water constitute.
3, according to the requirement of right 1, it is characterized in that, at method steps A) in applied resin be the Polar Adsorbent Resin that contains sulfoxide group.
4, according to the requirement of right 1, it is characterized in that, at method steps C) in applied elutriant composition be: water, a kind of can with the organic solvent of water mutual solubility, one or several are water insoluble or be slightly soluble in the organic solvent of water.
5, according to the requirement of right 1, it is characterized in that, at method steps C) in applied elutriant can be pH value neutrality; Perhaps PH is an alkalescence, and alkaline range is 8～13.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031138586A CN1332973C (en) | 2003-03-06 | 2003-03-06 | Extraction process of conjugated female hormone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031138586A CN1332973C (en) | 2003-03-06 | 2003-03-06 | Extraction process of conjugated female hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1526721A true CN1526721A (en) | 2004-09-08 |
| CN1332973C CN1332973C (en) | 2007-08-22 |
Family
ID=34283828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031138586A Expired - Fee Related CN1332973C (en) | 2003-03-06 | 2003-03-06 | Extraction process of conjugated female hormone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332973C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101949907A (en) * | 2010-06-30 | 2011-01-19 | 北京六角体科技发展有限公司 | Steroid pretreatment and detection method |
| US8129363B2 (en) | 2005-12-06 | 2012-03-06 | Xinjiang Tefeng Pharmaceutical Co., Ltd. | Method for obtaining conjugated estrogen mixtures from pregnant mare urine and use of a macroporous resin in the method |
| CN114588179A (en) * | 2020-12-03 | 2022-06-07 | 中国科学院大连化学物理研究所 | Method for separating and purifying conjugated estrogens from pregnant mare urine by using preparative chromatography |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228765B1 (en) * | 1996-08-30 | 2013-05-28 | Abbott Products Gmbh | Process to obtain oestrogens from mare's urine |
| CA2263757C (en) * | 1996-08-30 | 2007-10-23 | Solvay Deutschland Gmbh | Method to obtain oestrogens from mare's urine |
| CN1278432A (en) * | 1999-06-22 | 2001-01-03 | 中国科学院新疆化学研究所 | Method of extracting female hormone from pregnant woman's urine |
| CN1133639C (en) * | 2001-02-19 | 2004-01-07 | 中国科学院新疆化学研究所 | Extraction method of combined mixed estrin of pregnant mare |
| CN1240397C (en) * | 2001-04-18 | 2006-02-08 | 台湾神隆股份有限公司 | Process for preparing conjugated oestrogens from urine of pregnant mare |
-
2003
- 2003-03-06 CN CNB031138586A patent/CN1332973C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129363B2 (en) | 2005-12-06 | 2012-03-06 | Xinjiang Tefeng Pharmaceutical Co., Ltd. | Method for obtaining conjugated estrogen mixtures from pregnant mare urine and use of a macroporous resin in the method |
| CN101949907A (en) * | 2010-06-30 | 2011-01-19 | 北京六角体科技发展有限公司 | Steroid pretreatment and detection method |
| CN114588179A (en) * | 2020-12-03 | 2022-06-07 | 中国科学院大连化学物理研究所 | Method for separating and purifying conjugated estrogens from pregnant mare urine by using preparative chromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332973C (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106349324B (en) | The method of extraction separation crataegolic acid from olive growing leaves | |
| CN100439319C (en) | Method for preparing salviol acid A | |
| CN1962592A (en) | Method for separating and purifying polydatin and resveratrol from traditional Chinese medicine giant knotweed | |
| CN108403950A (en) | A kind of extraction and purification method of dendrobium candidum leaf flavonoids | |
| CN104000840A (en) | Preparation method of extractive containing gastrodin and gastrodia elata polysaccharide | |
| CN112266399B (en) | High-purity separation and extraction method of epimedium extract | |
| CN104119229A (en) | Technology for producing pure chlorogenic acid | |
| CN1332973C (en) | Extraction process of conjugated female hormone | |
| CN107629140A (en) | A kind of method of ionic liquid double-aqueous phase system extraction Goods-Flow Plan | |
| CN105175426B (en) | A kind of method of the extraction purification Bergenin from treebine stem | |
| CN107573396B (en) | Method for purifying and preparing high-purity chenodeoxycholic acid by utilizing chromatography-3 and dynamic axial compression column chromatography | |
| CN105031178A (en) | Extracting refining method making efficient utilization of anemarrhena asphodeloides | |
| CN106421286A (en) | Process for separating and purifying trillium steroid saponin by using macroporous resin | |
| NO318390B1 (en) | Process for the preparation of oestrogens from jump urine. | |
| CN106397529B (en) | The method of extraction separation crataegolic acid from olive pomace | |
| CN106336440B (en) | The method of extraction separation oleanolic acid from olive growing leaves | |
| CN113150052B (en) | Method for purifying quercetin glycoside in pepperweed seed | |
| CN1133639C (en) | Extraction method of combined mixed estrin of pregnant mare | |
| CN102920727A (en) | Method for preparing extracts rich in vitexin rhamnoside and vitexin glucoside | |
| CN1303052C (en) | Process for preparing Danshensu | |
| CN106349321B (en) | The method of extraction separation oleanolic acid from olive pomace | |
| CN114805466B (en) | Preparation method of hedera helix extract | |
| CN102233067A (en) | Method for extracting cattail pollen total flavonoids by double aqueous phases | |
| CN110066306A (en) | A kind of Isorhamnetin-3-O-neohespeidoside preparative liquid chromatography separation method | |
| CN102532248B (en) | Method for preparing trigonella foenum-graecum saponin B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20051230 Address after: Nanshan District Ma Liuzhou Industrial Zone of Shenzhen City, Guangdong Province, building 202 day flight Applicant after: Shenzhen Hadak Industrial Co.,Ltd. Address before: Nanshan District Ma Liuzhou Industrial Zone of Shenzhen City, Guangdong Province, building 202 day flight Applicant before: Zhou Tao Co-applicant before: Wang Yongli Co-applicant before: Jiang Feng |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Tao Document name: Notification of registration procedures and notice of patent for invention |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Tao Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |